Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akebia Therapeutics (AKBA – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report).
Akebia Therapeutics (AKBA)
Needham analyst Serge Belanger maintained a Hold rating on Akebia Therapeutics today. The company’s shares closed last Tuesday at $0.41, close to its 52-week low of $0.35.
According to TipRanks.com, Belanger has 0 stars on 0-5 stars ranking scale with an average return of
Akebia Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.00, a 426.2% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Hold rating on the stock with a $2.00 price target.
Cerevel Therapeutics Holdings (CERE)
Berenberg Bank analyst Esther Hong reiterated a Buy rating on Cerevel Therapeutics Holdings today and set a price target of $44.00. The company’s shares closed last Tuesday at $23.03.
According to TipRanks.com, Hong ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Cerevel Therapeutics Holdings is a Strong Buy with an average price target of $42.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AKBA: